UOC
TTPH

UBS O'Connor’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

UBS O'Connor’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,000
Closed -$3.8M – 828
2015
Q2 		$3.8M Buy
4,000
+570
+17% +$466K 0.03% 348
2015
Q1 		$2.51M Buy
+3,430
New +$2.58M 0.02% 375
2013
Q3 		– Sell
-1,550
Closed -$218K – 602
2013
Q2 		$218K Buy
+1,550
New +$245K ﹤0.01% 451

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

UBS O'Connor's TTPH Position: Q3 2015 in Review

UBS O'Connor sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2015, closing a stake of 4,000 shares — an estimated $3.8M sold.

UBS O'Connor first reported a position in TTPH in Q2 2013 and held it in 3 quarters. The position peaked at $3.8M in Q2 2015. 105 funds tracked by Wall St. Rank hold TTPH as of Q3 2015.

  • UBS O'Connor reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • UBS O'Connor sold 4,000 Tetraphase Pharmaceuticals, Inc. shares in Q3 2015, an estimated $3.8M.
  • UBS O'Connor first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
  • UBS O'Connor's Tetraphase Pharmaceuticals, Inc. position peaked at $3.8M in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2015.

Based on UBS O'Connor's 13F filing for Q3 2015, filed 13 Nov 2015.